FDA Clears Boston Scientific's TheraSphere 360 Y-90 Management Platform

FDA cleared the TheraSphere 360 Y-90 Management Platform, a treatment planning system for yttrium-90 radioembolization, from Boston Scientific via 510(k) pathway.

• The device is classified under FDA product code LLZ (Radiation Therapy Treatment Planning System) and was reviewed by the Radiology committee.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.